Response to letter re: Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysis.

Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Diogo Martins-Branco: Full time employment at European Society for Medical Oncology since September 1, 2023; speaker’s engagement from Daiichi Sankyo/AstraZeneca; participation as medical research fellow in research studies institutionally funded by Eli Lilly, Novartis, and F. Hoffmann-La Roche Ltd to Institut Jules Bordet; non-financial interest as member of the board of directors for Associaҫão de Investigaҫão e Cuidados de Suporte em Oncologia (all outside the submitted work); Guilherme Nader-Marta: Support to attend medical conferences: AstraZeneca (all outside the submitted work); Chiara Molinelli: Honoraria and advisory board fees from Daiichi Sankyo and Novartis, medical writing by Lilly and Seagen, travel support for attending conferences by Gilead; research grant from Fondazione Umberto Veronesi (all outside the submitted work); Evandro de Azambuja: Honoraria and/or advisory board from Roche/GNE, Novartis, SeaGen, Zodiac, Libbs; Pierre Fabre, Lilly, Astra-Zeneca, MSD, and Gilead. Travel grants from Roche/GNE and Astra-Zeneca. Research grant to my institution from Roche/GNE, Astra-Zeneca, GSK/Novartis and Servier (all outside the submitted work). Lieveke Ameye has no conflicts of interest to declare.